Registrant's
telephone number, including area code
(631)
421-5452
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended
to
simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
] Written communications pursuant to Rule 425 under the Securities Act 17 CFR
230.425)
[
] Soliciting material pursuant to Rule l4a-12 under the Exchange
Act
(17
CFR 240.l4a-12)
[
] Pre-commencement communications pursuant to Rule l4d- 2(b) under the Exchange
Act
(17
CFR 240. l4d- 2(b)
[
] Pre-commencement communications pursuant to Rule 13 e-4( c) under the Exchange
Act
(17
CFR 240.13 e-4( c)
Item
8.01
OTHER
EVENTS
SEE
ATTACHED EXHIBIT
EXHIBITS:
99.1
Press
Release October 11, 2006 announcing Bovie Medical Corporation’s Exclusive
Distribution Agreement with Boston Scientific for Electro Surgery Oncology
Product.
99.2
Press
Release October 12, 2006 announcing Bovie Medical Corporation’s receipt of US
Food and Drug Administration (FDA) clearance to market new Laparoscopic
instruments.
BOVIE
MEDICAL CORPORATION
By:
_____________________
ANDREW
MAKRIDES
President
EXHIBIT
99.1
BOVIE
MEDICAL ANNOUNCES EXCLUSIVE DISTRIBUTION AGREEMENT WITH BOSTON SCIENTIFIC FOR
ELECTROSURGERY ONCOLOGY PRODUCT
Melville,
NY - October 11, 2006 - Bovie Medical Corporation (“Bovie”) (AMEX:BVX), a
manufacturer and marketer of electrosurgical products, announced today that
it
has entered into an agreement with Boston Scientific Corporation (NYSE: BSX)
for
the exclusive distribution and marketing by Boston Scientific of an
electrosurgical device for use in Boston Scientific’s Oncology business.
Under the agreement, Bovie will manufacture the product. The product will be
co-labeled with both the Boston Scientific and Bovie names displayed.
Additionally, Bovie will receive funding from Boston Scientific as part of
its
manufacturing start up.
Commenting
on the agreement, Bovie president Andrew Makrides stated, “We are pleased to be
working with one of the premier medical device companies in the world. It
is a strong step forward in our strategy to achieve greater market recognition
through Boston Scientific’s well-established and expert sales force. Bovie
looks ahead to a continued mutually beneficial relationship with Boston
Scientific.”
About
Boston Scientific
Boston
Scientific is a worldwide developer, manufacturer and marketer of medical
devices whose products are used in a broad range of interventional medical
specialties. For more information, please visit: www.bostonscientific.com.
.
About
Bovie Medical
Bovie
Medical Corporation, headquartered in Melville, NY, with manufacturing in St.
Petersburg, FL, is a developer, manufacturer and marketer of electrosurgical
products. For more information, please visit: www.boviemedical.com.
BOVIE
MEDICAL CORPORATION ANNOUNCES FDA CLEARANCE TO MARKET NEW LAPAROSCOPIC
INSTRUMENTS
Melville,
New York, Oct 12, 2006 - Bovie Medical Corporation (the “Company”) (Amex: BVX),
a manufacturer and marketer of electrosurgical products, today announced that
it
has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market
a new line of patent pending advanced modular laparoscopic electrosurgical
electrodes and handle, aimed at the laparoscopic and arthroscopic markets.
The
Modular Ergonomic Instruments (MEG) family combined with Bovie’s advanced
electrosurgical generators offers users unprecedented cost savings as well
as
reduced and simplified inventory.
The
high
quality, reusable, insulated MEG line handle comes with light metallic grips,
transparent ratchet and ergonomic design, which is expected to reduce surgeon
fatigue and improve tactile feel. The handle accepts reusable tip inserts.
Additionally, the loading and detachment of tips is simple with minimal required
user training.
It
is
estimated that the total annual worldwide market for this product line exceeds
$200 million.
In
other
news, the Company announced that Mr. Gary Pickett has been promoted to Chief
Financial Officer. Mr. Pickett has been the Company's Controller since
March 27, 2006.
Mr.
Pickett previously held financial and accounting positions with Progress Rail
Services, Progress Energy and Florida Power Corporation. Mr. Pickett is a
CPA with extensive experience in Sarbanes-Oxley implementation as well as GAAP
accounting and SEC reporting. He holds an MBA from Tampa University, B.S.
from Florida State and served five years as a field artillery officer in the
United States Army.
This
document may contain some forward looking statements, particularly regarding
operational prospects in 2006 and beyond, which involve a number of risks and
uncertainties that could cause actual results to differ materially. These risks
are listed from time to time in the Company’s SEC filings.
